🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Naltrexone is not contraindicated in cirrhosis There is no evidence of harm Only evidence of benefit Do we know for certain it is safe in Child C cirrhosis? No! Nothing is certain in child C cirrhosis.

📢 #ANRFIndia Invites Applications for National Post-Doctoral Fellowship (NPDF)! Shape your research journey with support from Anusandhan National Research Foundation 🗓️Application Period: 1 June 2025 – 30 June 2025 🔗For more, visit: anrfonline.in/ANRF/npdf #researchgrant #NPDF

📜 ⚠️ 🔸The Punjab HCVModel reveals newer 📜RAS in HCV 🔸Another mammoth 📝 led by M PREMKUMAR Ajay Duseja Dr Nipun Verma Arka De Having seen this project frm close quarters 🫡 1️⃣of largest programs with public health impact in 🇮🇳🌏 director.sgpgi 👇🏽 jcehepatology.com/article/S0973-…

📣New data on cirrhosis recompensation in Journal of Hepatology ✅Only 7% meets strict Baveno VII criteria ✅Expanded criteria capture ~38% with similar low mortality risk Recompensation: ⬇️systemic inflammation🔥 👍 improved hemodynamic ⬆️improved survival doi.org/10.1016/j.jhep…

Artifcial intelligence-assisted academic writing: recommendations for ethical use (1/5)

Did You Know? Fatty Liver Disease can strike without a single sip of alcohol - and it's far more common than you think. फैटी लिवर बीमारी शराब पीए बिना भी हो सकती है - और ये सोचने से कहीं ज़्यादा आम है। Want to learn more? Click here: youtu.be/6W0ehayZmpk?si…

❗Serum proteomics of adults with acute liver failure provides mechanistic insights and attractive prognostic biomarkers 🔓#OpenAccess at 👉 jhep-reports.eu/article/S2589-… #LiverX #LiverTwitter #LiverFailure

High throughput data are goldmines that we often only scratch the surface. Great for AI to systematically analyze! CellVoyager makes Jupyter notebooks 📜biorxiv.org/content/10.110… 💻github.com/zou-group/Cell… Great job Samuel Alber Bowen Chen Eric Sun Aaron Wilk Alina Isakova

Eid Mubarak to Everyone. Wishing Everyone Good Health and Happiness.

#CRLP faculty Jas Bajaj research success tips: ▶️Time to think where your research is going ▶️Broaden your research portfolio but stay true to your passsion ▶️Focus on mentorship, collaboration and legacy building Millie Long Brennan Spiegel, MD, MSHS ACG Neena S Abraham MD MACG FASGE AGAF

More data on the "Methotrexate Myth" Coming from the 🇮🇳DILI master #harshaddevarbhavi Look at co-morbidities before the judgment INASL Liver Fellow Network Elliot Tapper Anand V Kulkarni M PREMKUMAR Ajay Duseja TheLiverDoc Dr Nipun Verma jcehepatology.com/article/S0973-…

Using Abb MRI for Liver Imaging Checkout the proposed Abb-MRI classification #pankajgupta Ajay Duseja M PREMKUMAR Dr Nipun Verma INASL Liver Fellow Network 👇🏽 jcehepatology.com/article/S0973-…

📷 New from PGI Chandigarh! 📷 #PankajGupta et al propose a simple non-contrast Abbreviated MRI (T2W, DWI) to categorize liver lesions in CLD—no contrast needed! 3 clear categories: Benign, Equivocal, Malignant 88% accuracy in real-world patients doi.org/10.1016/j.jceh…

INASL-2025 Chandigarh - 7-10th August, 2025 MASLD Symposium on 7th August, 2025 Covering all aspects of #MASLD Register Now- inasl2025.com Sunil Taneja M PREMKUMAR Dr Nipun Verma Arka De NAVEEN BHAGAT Dr.Babu Lal Meena Hepatology PGI Arun J. Sanyal Maru Rinella MD

Today, we unite to raise awareness about the rising menace of fatty liver disease that afflicts millions worldwide! "Act Now, Screen Today"! INASL Global Fatty Liver Day FattyLiverAlliance EASLnews AASLD AARC_APASL Ajay Duseja Dr Nipun Verma

Global Fatty Liver Day!! “Fatty Liver is Preventable! Control Diabetes, Hypertension, Obesity, and Dyslipidemia.” Healthy Diet and Regular Exercise can do wonders !!! INASL Ajay Duseja M PREMKUMAR Arka De Dr Nipun Verma Sahaj Rathi MD, DM, MRCP Rohit Mehtani Akash Roy EASLnews

👆Happy to share this latest publication from our group. This publication is very dear to me. Grateful to all my coauthors but especially to Prajna Anirvan for his tireless efforts in getting this published. Jonathan G. Stine, MD MSc, FACP This is esp for you EASLnews AASLD APASL News

New data w/Rohit Loomba MASLD Research Center on extended-release naltrexone (XR-NTX) in advanced ALD: In this case series, XR-NTX was well tolerated in patients with compensated ALD (64% cirrhosis)— no hepatotoxicity, no severe adverse events. 👉 doi.org/10.1111/apt.70… #LiverTwitter

The integration of multi-omics with artificial intelligence in hepatology: a comprehensive review of personalized medicine, biomarker identification, and drug discovery ⁦Journal of Clinical and Experimental Hepatology⁩ ⁦INASL⁩ ⁦AASLD⁩ ⁦Mamatha Bhat⁩ jcehepatology.com/article/S0973-…

It's finally here! Consensus #ACLF & #cirrhosis organ failure definitions. Gastroenterology ⤵️ pubmed.ncbi.nlm.nih.gov/40499736/ Why? We need to speak the same language re #ACLF for #transplant/new Rx dev How? Multi-country consensus panels Result? Harmonized definitions &  research agenda